Outsourcing Boasts Growth
Outsourced manufacturing set to grow by 6.6 percent over the next four years, according to Results Healthcare
James Strachan |
Results Healthcare have published a review of outsourced manufacturing in pharma and biotech – and the news is good for the sector (1). The headline figure is an expected growth figure of 6.6 percent – well above the expected global GDP growth. This, the authors claim, is driven by the strong growth of the overall pharmaceutical sector, as well as an increase in the amount of outsourced manufacturing work. Over the next four years, growth is expected to be dedicated to small molecules and commercial manufacturing supply. Here are some of the key findings.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.